SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
MIST reported Third Quarter 2026 results. The price and volatility reaction is pending.
MISTearnings

Earnings reactions, page 2

Milestone Pharmaceuticals Inc. (MIST) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • Net product revenue for CARDAMYST was $1.0 million for the three months ended September 30, 2026.
  • Research and development expense, net of tax credits, was $3.5 million for the three months ended September 30, 2026.
  • Selling, general and administrative expense was $24.2 million for the three months ended September 30, 2026.
  • Net loss was $25.8 million, or $0.18 per share, for the three months ended September 30, 2026.
  • Cash, cash equivalents, and short-term investments totaled $145.4 million as of September 30, 2026.

Guidance

  • Company expects cash, cash equivalents and short-term investments to be sufficient to cover operating expenses and capital expenditure into late 2028.
  • Company expects to reduce operating expenses by approximately 30%.
  • Company expects to incur approximately $2 million in one-time charges related to cost-efficiency measures.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-13 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →